Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9512992 | 0.81 | FDPS (0.41) | FDPSCA12CA1CA2MMP1 | |
| SCHEMBL27666450 | 0.77 | PPARD (0.43) | FDPSCYP2C19 | |
| SCHEMBL3904202 | 0.76 | FDPS (0.48) | FDPSLMNAMMP2LAP3 | |
| SCHEMBL56898 | 0.76 | FDPS (0.48) | FDPSLMNAMMP2LAP3 | |
| SCHEMBL9509819 | 0.75 | LAP3 (0.37) | FDPSLMNACYP2C19CA12CA1 | |
| SCHEMBL31522308 | 0.74 | FDPS (0.45) | FDPS | |
| SCHEMBL1877265 | 0.73 | FDPS (0.46) | FDPSMMP2LAP3 | |
| SCHEMBL31122734 | 0.73 | FDPS (0.46) | FDPSMMP2LAP3 | |
| SCHEMBL10619694 | 0.73 | FDPS (0.46) | FDPSMMP2LAP3 | |
| SCHEMBL32670822 | 0.73 | FDPS (0.46) | FDPSMMP2LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025091709-A1 | SECONDARY BATTERY AND PREPARATION METHOD THEREFOR, AND ELECTRIC DEVICE | 宁德时代新能源科技股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| US-7005533-B2 | Bisphosphonate derivatives, their preparations and uses | UNIVERSITE PARIS 13 (FR) | 2006-02-28 | — | — | US | disclosed |
| US-20040266735-A1 | Bisphosphonate derivatives, their preparations and uses | UNIVERSITE PARIS 13 | 2004-12-30 | — | — | US | disclosed |
| US-20030036537-A1 | Bisphosphonate derivatives, their preparations and uses | UNIVERSITE PARIS, 13 (FR) | 2003-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036537-A1 | Bisphosphonate derivatives, their preparations and uses | BPGM, PPIP5K2, PTEN | FDPS 36/4885LMNA 2357/4885CYP2C19 793/4885 |
| US-20040266735-A1 | Bisphosphonate derivatives, their preparations and uses | BPGM, PPIP5K2, PTEN | FDPS 36/4885LMNA 2357/4885CYP2C19 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.